Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
5.
Actas dermo-sifiliogr. (Ed. impr.) ; 113(9): 881-887, oct. 2022. tab
Article in English | IBECS | ID: ibc-210366

ABSTRACT

Background and aims A dermal inflammatory infiltrate rich in eosinophils is a prominent histological feature of bullous pemphigoid (BP) and peripheral blood eosinophilia has been documented in 50–60% of BP patients. Nevertheless, the impact of circulating and dermal infiltrate eosinophil levels on BP remains poorly understood. The main objective of this work was to investigate the association of peripheral blood and dermal infiltrate eosinophil levels with clinical and immunological characteristics of the disease. Material and methods Retrospective cohort study including all patients diagnosed with BP between 2011 and 2020. Results The study cohort included 233 patients with BP. The mean baseline peripheral blood eosinophil count was 956.3±408.6×106/L and the mean number of tissue eosinophils at the dermal hot spot area was 30.5±19.0. Patients with disseminated presentation (i.e. BSA>50%) had significantly higher peripheral blood eosinophil counts (P=0.028). Mucosal involvement was significantly associated with lower dermal eosinophil count (P=0.001). Requiring inpatient care and relapsing were significantly associated with high peripheral blood eosinophil count (P=0.025; P=0.020, respectively). Among the 68 patients who experienced a relapse, 31 had peripheral blood eosinophilia (i.e. >500×106/L) at relapse (44.2%). Peripheral blood eosinophil counts at baseline and at relapse were significantly correlated (r=0.82, P<0.001). Conclusion Peripheral blood and cutaneous eosinophils levels may be useful biomarkers for disease activity and treatment outcomes in BP. Monitoring peripheral blood eosinophil counts may allow early detection of relapse (AU)


Antecedentes y objetivos El infiltrado inflamatorio dérmico rico en eosinófilos es una característica histológica destacada de penfigoide ampolloso (PA) y eosinofilia en sangre periférica, que se ha documentado en el 50-60% de los pacientes con esta enfermedad. Sin embargo, el impacto de los niveles de eosinófilos circulantes y en infiltrados dérmicos en el PA sigue sin comprenderse. El objetivo principal de este estudio fue investigar la asociación entre los niveles de eosinófilos en sangre periférica y en infiltrados dérmicos y las características clínicas e inmunológicas de esta enfermedad. Material y métodos Estudio de cohorte retrospectivo que incluyó a todos los pacientes con PA entre 2011 y 2020. Resultados El estudio de cohorte incluyó 233 pacientes con PA. El recuento de eosinófilos basal medio en sangre periférica fue de 956,3 ± 408,6 x106/L y el número medio de eosinófilos tisulares en la zona dérmica clave fue de 30,5 ± 19. Los pacientes con presentación diseminada (es decir, BSA >50%) tuvieron conteos de eosinófilos en sangre periférica significativamente superiores (p = 0,028). El compromiso mucoso estuvo significativamente asociado a un conteo de eosinófilos cutáneo inferior (p = 0,001). La necesidad de cuidados hospitalarios y las recaídas estuvieron significativamente asociadas a conteos de eosinófilos en sangre periférica más elevados (p = 0,025; p = 0,020, respectivamente). Entre los 68 pacientes que experimentaron recidiva, 31 tuvieron eosinofilia en sangre periférica (es decir, > 500 x 106/L) en recaída (44,2%). Los conteos de eosinófilos en sangre periférica basales y en recaída se correlacionaron significativamente (r = 0,82, p < 0,001). Conclusione Los niveles de eosinófilos en sangre periférica y cutáneos pueden constituir biomarcadores útiles para la actividad de la enfermedad y los resultados terapéuticos en el PA. Supervisar los conteos de eosinófilos en sangre periférica puede ayudar a detectar la recidiva tempranamente (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Pemphigoid, Bullous/drug therapy , Pemphigoid, Bullous/pathology , Eosinophils/pathology , Severity of Illness Index , Treatment Outcome , Retrospective Studies , Cohort Studies , Recurrence
6.
Actas dermo-sifiliogr. (Ed. impr.) ; 113(9): t881-t887, oct. 2022. tab
Article in Spanish | IBECS | ID: ibc-210367

ABSTRACT

Antecedentes y objetivos El infiltrado inflamatorio dérmico rico en eosinófilos es una característica histológica destacada de penfigoide ampolloso (PA) y eosinofilia en sangre periférica, que se ha documentado en el 50-60% de los pacientes con esta enfermedad. Sin embargo, el impacto de los niveles de eosinófilos circulantes y en infiltrados dérmicos en el PA sigue sin comprenderse. El objetivo principal de este estudio fue investigar la asociación entre los niveles de eosinófilos en sangre periférica y en infiltrados dérmicos y las características clínicas e inmunológicas de esta enfermedad. Material y métodos Estudio de cohorte retrospectivo que incluyó a todos los pacientes con PA entre 2011 y 2020. Resultados El estudio de cohorte incluyó 233 pacientes con PA. El recuento de eosinófilos basal medio en sangre periférica fue de 956,3 ± 408,6 x106/L y el número medio de eosinófilos tisulares en la zona dérmica clave fue de 30,5 ± 19. Los pacientes con presentación diseminada (es decir, BSA >50%) tuvieron conteos de eosinófilos en sangre periférica significativamente superiores (p = 0,028). El compromiso mucoso estuvo significativamente asociado a un conteo de eosinófilos cutáneo inferior (p = 0,001). La necesidad de cuidados hospitalarios y las recaídas estuvieron significativamente asociadas a conteos de eosinófilos en sangre periférica más elevados (p = 0,025; p = 0,020, respectivamente). Entre los 68 pacientes que experimentaron recidiva, 31 tuvieron eosinofilia en sangre periférica (es decir, > 500 x 106/L) en recaída (44,2%). Los conteos de eosinófilos en sangre periférica basales y en recaída se correlacionaron significativamente (r = 0,82, p < 0,001). Conclusione Los niveles de eosinófilos en sangre periférica y cutáneos pueden constituir biomarcadores útiles para la actividad de la enfermedad y los resultados terapéuticos en el PA. Supervisar los conteos de eosinófilos en sangre periférica puede ayudar a detectar la recidiva tempranamente (AU)


Background and aims A dermal inflammatory infiltrate rich in eosinophils is a prominent histological feature of bullous pemphigoid (BP) and peripheral blood eosinophilia has been documented in 50–60% of BP patients. Nevertheless, the impact of circulating and dermal infiltrate eosinophil levels on BP remains poorly understood. The main objective of this work was to investigate the association of peripheral blood and dermal infiltrate eosinophil levels with clinical and immunological characteristics of the disease. Material and methods Retrospective cohort study including all patients diagnosed with BP between 2011 and 2020. Results The study cohort included 233 patients with BP. The mean baseline peripheral blood eosinophil count was 956.3±408.6×106/L and the mean number of tissue eosinophils at the dermal hot spot area was 30.5±19.0. Patients with disseminated presentation (i.e. BSA>50%) had significantly higher peripheral blood eosinophil counts (P=0.028). Mucosal involvement was significantly associated with lower dermal eosinophil count (P=0.001). Requiring inpatient care and relapsing were significantly associated with high peripheral blood eosinophil count (P=0.025; P=0.020, respectively). Among the 68 patients who experienced a relapse, 31 had peripheral blood eosinophilia (i.e. >500×106/L) at relapse (44.2%). Peripheral blood eosinophil counts at baseline and at relapse were significantly correlated (r=0.82, P<0.001). Conclusion Peripheral blood and cutaneous eosinophils levels may be useful biomarkers for disease activity and treatment outcomes in BP. Monitoring peripheral blood eosinophil counts may allow early detection of relapse (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Pemphigoid, Bullous/drug therapy , Pemphigoid, Bullous/pathology , Eosinophils/pathology , Severity of Illness Index , Treatment Outcome , Retrospective Studies , Cohort Studies , Recurrence
8.
Actas Dermosifiliogr ; 113(9): 881-887, 2022 Oct.
Article in English, Spanish | MEDLINE | ID: mdl-35659610

ABSTRACT

BACKGROUND AND AIMS: A dermal inflammatory infiltrate rich in eosinophils is a prominent histological feature of bullous pemphigoid (BP) and peripheral blood eosinophilia has been documented in 50-60% of BP patients. Nevertheless, the impact of circulating and dermal infiltrate eosinophil levels on BP remains poorly understood. The main objective of this work was to investigate the association of peripheral blood and dermal infiltrate eosinophil levels with clinical and immunological characteristics of the disease. MATERIAL AND METHODS: Retrospective cohort study including all patients diagnosed with BP between 2011 and 2020. RESULTS: The study cohort included 233 patients with BP. The mean baseline peripheral blood eosinophil count was 956.3±408.6×106/L and the mean number of tissue eosinophils at the dermal hot spot area was 30.5±19.0. Patients with disseminated presentation (i.e. BSA>50%) had significantly higher peripheral blood eosinophil counts (P=0.028). Mucosal involvement was significantly associated with lower dermal eosinophil count (P=0.001). Requiring inpatient care and relapsing were significantly associated with high peripheral blood eosinophil count (P=0.025; P=0.020, respectively). Among the 68 patients who experienced a relapse, 31 had peripheral blood eosinophilia (i.e. >500×106/L) at relapse (44.2%). Peripheral blood eosinophil counts at baseline and at relapse were significantly correlated (r=0.82, P<0.001). CONCLUSIONS: Peripheral blood and cutaneous eosinophils levels may be useful biomarkers for disease activity and treatment outcomes in BP. Monitoring peripheral blood eosinophil counts may allow early detection of relapse.


Subject(s)
Eosinophilia , Pemphigoid, Bullous , Biomarkers , Eosinophilia/pathology , Eosinophils/pathology , Humans , Pemphigoid, Bullous/drug therapy , Recurrence , Retrospective Studies , Severity of Illness Index , Treatment Outcome
10.
Exp Appl Acarol ; 76(4): 421-433, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30357575

ABSTRACT

Varroa destructor is one of the major pests that affect honeybees around the world. Chemical treatments are common to control varroosis, but mites possess biochemical adaptive mechanisms to resist these treatments, enabling them to survive. So far, no information is available regarding whether these pesticides can induce the expression of heat shock protein (Hsp) as a common protective mechanism against tissue damage. The aims of this study were to determine differences in heat shock tolerance between mites collected from brood combs and phoretic ones, and to examine patterns of protein expression of Hsp70 that occur in various populations of V. destructor after exposure to acaricides commonly employed in beekeeping, such as flumethrin, tau-fluvalinate and coumaphos. Curiously, mites obtained from brood cells were alive at 40 °C, unlike phoretic mites that reached 100% mortality, demonstrating differential thermo-tolerance. Heat treatment induced Hsp70 in mites 4 × more than in control mites and no differences in response were observed in phoretic versus cell-brood-obtained mites. Dose-response assays were carried out at increasing acaricide concentrations. Each population showed a different stress response to acaricides despite belonging to the same geographic region. In one of them, coumaphos acted as a hormetic stressor. Pyrethroids also induced Hsp70, but mite population seemed sensitive to this treatment. We concluded that Hsp70 could represent a robust biomarker for measuring exposure of V. destructor to thermal and chemical stress, depending on the acaricide class and interpopulation variability. This is relevant because it is the first time that stress response is analyzed in this biological model, providing new insight in host-parasite-xenobiotic interaction.


Subject(s)
Acaricides/pharmacology , Arthropod Proteins/genetics , HSP70 Heat-Shock Proteins/genetics , Hot Temperature/adverse effects , Varroidae/physiology , Animals , Arthropod Proteins/metabolism , Coumaphos/pharmacology , Female , HSP70 Heat-Shock Proteins/metabolism , Nitriles/pharmacology , Pyrethrins/pharmacology , Stress, Physiological , Varroidae/drug effects , Varroidae/genetics
11.
Dermatol Online J ; 24(6)2018 Jun 15.
Article in English | MEDLINE | ID: mdl-30142721

ABSTRACT

The abrupt development of multiple melanocytic nevi has been described in association with many conditions, including human immunodeficiency virus infection. We report three cases of eruptive nevi in men with human immunodeficiency virus type 1 infection. One patient developed this phenomenon during the stage of acquired immunodeficiency syndrome. The other two patients had human immunodeficiency virus infection recently diagnosed and presented to our clinic reporting the development of multiple melanocytic nevi after starting highly active antiretroviral treatment, with improvement of their immunity. To our knowledge, this is the first report of eruptive melanocytic nevi as a possible consequence of the immune reconstitution inflammatory syndrome.


Subject(s)
Antiretroviral Therapy, Highly Active/adverse effects , HIV Infections/complications , Immune Reconstitution Inflammatory Syndrome/complications , Nevus, Pigmented/etiology , Skin Neoplasms/etiology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/drug therapy , Adult , HIV Infections/drug therapy , Humans , Middle Aged , Young Adult
12.
Benef Microbes ; 9(2): 279-290, 2018 Feb 27.
Article in English | MEDLINE | ID: mdl-29264966

ABSTRACT

Due to their social behaviour, honey bees can be infected by a wide range of pathogens including the microsporidia Nosema ceranae and the bacteria Paenibacillus larvae. The use of probiotics as food additives for the control or prevention of infectious diseases is a widely used approach to improve human and animal health. In this work, we generated a mixture of four Lactobacillus kunkeei strains isolated from the gut microbial community of bees, and evaluated its potential beneficial effect on larvae and adult bees. Its administration in controlled laboratory models was safe for larvae and bees; it did not affect the expression of immune-related genes and it was able to decrease the mortality associated to P. larvae infection in larvae and the counts of N. ceranae spores from adult honey bees. These promising results suggest that this beneficial microorganism's mixture may be an attractive strategy to improve bee health. Field studies are being carried out to evaluate its effect in naturally infected colonies.


Subject(s)
Antibiosis , Bees/microbiology , Dietary Supplements , Lactobacillus/physiology , Probiotics , Animal Feed , Animals , Gastrointestinal Microbiome/physiology , Larva/growth & development , Nosema/physiology , Paenibacillus larvae/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...